📊 RENXF Key Takeaways
Is Renalytix plc (RENXF) a Good Investment?
Renalytix faces existential financial distress with negative stockholders' equity of -$11.3M, indicating technical insolvency. The company burns $3.8M annually while revenue collapses 32.7% YoY to only $522K, leaving approximately 3 months of cash runway at $909K. Absent immediate capital infusion or dramatic operational turnaround, bankruptcy risk is severe.
Fundamentals indicate severe strain: revenue is contracting while operating and net margins remain deeply negative, driving heavy losses and a -98.6% ROA. Liquidity is critically tight (current ratio 0.24x; $0.9M cash) against significant liabilities and negative equity, implying high near-term financing risk. While losses narrowed and gross margin is positive, the business lacks sufficient scale to fund operations sustainably.
Renalytix plc Key Strengths (RENXF)
- Gross profit of $100K demonstrates core business model generates some positive contribution margin
- Operating and net losses improving YoY (26.6% and 43.6% respectively) suggests cost discipline
- No significant long-term debt obligations limiting downside complexity
- Positive gross margin (19%) indicates some unit economics
- YoY improvement in net loss and EPS suggests cost control progress
- Low capital intensity (zero capex) and minimal long-term debt burden
RENXF Stock Risks: Renalytix plc Investment Risks
- Negative stockholders' equity of -$11.3M: company is technically insolvent
- Critical liquidity crisis: current ratio of 0.24x with only $909K cash supporting -$3.8M annual operating burn
- Revenue collapse of -32.7% YoY indicates loss of customers and deteriorating business momentum
- Negative operating and free cash flows unsustainable without external capital or radical restructuring
- Estimated 3-month cash runway creates imminent solvency risk and potential for equity dilution or bankruptcy
- Zero insider buying activity indicates management has no confidence in recovery
- Imminent liquidity shortfall given low cash and high burn
- Declining revenue (-32.7% YoY) risks persistent extreme negative margins
- High likelihood of dilutive financing or restructuring due to negative equity
Key Metrics to Watch
- Monthly operating cash burn rate and cash balance depletion trajectory
- Quarterly revenue stabilization and customer retention metrics
- Capital raising announcements or debt restructuring activities
- Pathway to positive operating cash flow and cost reduction milestones
- Operating margin compression or expansion trends
- Cash & equivalents (runway)
- Operating cash flow (burn rate)
Renalytix plc (RENXF) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
RENXF Profit Margin, ROE & Profitability Analysis
RENXF vs Healthcare Sector: How Renalytix plc Compares
How Renalytix plc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Renalytix plc Stock Overvalued? RENXF Valuation Analysis 2026
Based on fundamental analysis, Renalytix plc has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Renalytix plc Balance Sheet: RENXF Debt, Cash & Liquidity
RENXF Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Renalytix plc's revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.55 indicates the company is currently unprofitable.
RENXF Revenue Growth, EPS Growth & YoY Performance
RENXF Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2025 | $459.0K | -$4.7M | $-0.04 |
| Q3 2024 | $535.0K | -$7.7M | $-0.08 |
| Q2 2024 | $709.0K | -$8.5M | $-0.09 |
| Q1 2024 | $459.0K | -$10.2M | $-0.11 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Renalytix plc Dividends, Buybacks & Capital Allocation
RENXF SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Renalytix plc (CIK: 0001811115)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RENXF
What is the AI rating for RENXF?
Renalytix plc (RENXF) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 92% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are RENXF's key strengths?
Claude: Gross profit of $100K demonstrates core business model generates some positive contribution margin. Operating and net losses improving YoY (26.6% and 43.6% respectively) suggests cost discipline. ChatGPT: Positive gross margin (19%) indicates some unit economics. YoY improvement in net loss and EPS suggests cost control progress.
What are the risks of investing in RENXF?
Claude: Negative stockholders' equity of -$11.3M: company is technically insolvent. Critical liquidity crisis: current ratio of 0.24x with only $909K cash supporting -$3.8M annual operating burn. ChatGPT: Imminent liquidity shortfall given low cash and high burn. Declining revenue (-32.7% YoY) risks persistent extreme negative margins.
What is RENXF's revenue and growth?
Renalytix plc reported revenue of $522.0K.
Does RENXF pay dividends?
Renalytix plc does not currently pay dividends.
Where can I find RENXF SEC filings?
Official SEC filings for Renalytix plc (CIK: 0001811115) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RENXF's EPS?
Renalytix plc has a diluted EPS of $-0.04.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is RENXF's fundamental grade?
Based on our AI fundamental analysis in June 2026, Renalytix plc has a D grade with 92% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is RENXF stock overvalued or undervalued?
Valuation metrics for RENXF: ROE of N/A (sector avg: 15%), net margin of -905.7% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is RENXF's AI grade for 2026?
Our dual AI analysis gives Renalytix plc a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RENXF's free cash flow?
Renalytix plc's operating cash flow is $-3.8M, with capital expenditures of $0.0. FCF margin is -734.9%.
How does RENXF compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -905.7% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.24 (avg: 2).